p53 Review Article

You have free access to this content

TP53 and breast cancer†

  1. Anne-Lise Børresen-Dale*

Article first published online: 24 FEB 2003

DOI: 10.1002/humu.10174

Issue

Human Mutation

Human Mutation

Special Issue: Focus on p53 and Cancer

Volume 21, Issue 3, pages 292–300, March 2003

Additional Information

How to Cite

Børresen-Dale, A.-L. (2003), TP53 and breast cancer. Hum. Mutat., 21: 292–300. doi: 10.1002/humu.10174

Author Information

  1. Department of Genetics, Institute for Cancer Research, The University Hospital, The Norwegian Radium Hospital, Montebello, Oslo, Norway

*Department of Genetics, Institute for Cancer Research, The University Hospital The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway

  1. †

    For the p53 Special Issue

Publication History

  1. Issue published online: 24 FEB 2003
  2. Article first published online: 24 FEB 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (133K)

Keywords:

  • breast cancer;
  • cancer;
  • tumor;
  • p53;
  • TP53;
  • loss of heterozygosity;
  • LOH;
  • Li-Fraumeni syndrome;
  • LFS

Abstract

The TP53 gene (p53) is found altered in breast carcinomas in approximately 20–40% of all cases depending on tumor size and stage of the disease. It seems to be an early event in breast tumorigenesis. Several polymorphisms in the TP53 gene have been detected and their possible roles in breast cancer risk and association to type of cancer developed are discussed. The different mutation spectra seen in geographical and ethnic populations may be used to identify environmental exposure contributing to breast cancer development. The role of TP53 mutation as a prognostic marker is reviewed as well as its role as a predictor for therapy response. All data available on TP53 mutation analyses of human breast carcinomas, as well data from transgenic animal studies and experimental cell studies, support an important role for TP53 in mammary carcinogenesis. Hum Mutat 21:292–300, 2003. © 2003 Wiley-Liss, Inc.

Get PDF (133K)